PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used for the treatment of lung cancer: A case report and literature review.

Abstract Drug-induced pancreatitis (DIP) is a rare type of pancreatitis that is not usually observed in the clinical practice. It is generally difficult to distinguish from acute pancreatitis (AP) induced by other causes.
PMID
Related Publications

Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation.

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer.

Acute pancreatitis induced by ifosfamide therapy.

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28723805
OWN - NLM
STAT- MEDLINE
DA  - 20170720
DCOM- 20170808
LR  - 20170808
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 29
DP  - 2017 Jul
TI  - Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used 
      for the treatment of lung cancer: A case report and literature review.
PG  - e7601
LID - 10.1097/MD.0000000000007601 [doi]
AB  - RATIONALE: Drug-induced pancreatitis (DIP) is a rare type of pancreatitis that is
      not usually observed in the clinical practice. It is generally difficult to
      distinguish from acute pancreatitis (AP) induced by other causes. PATIENT
      CONCERNS: Here, we report a 62-year-old Chinese female patient with "small cell
      lung cancer" as the initial presentation. Because the patient could not bear the 
      surgical treatment, the chemotherapy composed of lobaplatin and etoposide was
      performed. Three days later, the patient displayed sudden abdominal pain,
      distension, nausea, and vomiting without obvious inducements. Laboratory tests
      showed that the levels of serum and urine amylase were enhanced; abdominal
      computed tomography (CT) result showed the enlargement of the pancreas,
      peripancreatic effusion, and a rough edge, which suggested the diagnosis of AP.
      The patient had no history of biliary tract disease, alcoholism, binge
      overeating, hyperlipidemia, and hereditary pancreatitis. DIAGNOSES: The patient
      was diagnosed with DIP. INTERVENTIONS: The chemotherapy was stopped at once and
      we performed fluid resuscitation, pain alleviation, prophylactic antibiotics, and
      nutritional support, etc on the patient. Later, the patient's clinical symptoms
      were obviously relieved, and she recovered successfully. OUTCOMES: The
      chemotherapy was continued, but later, the patient showed abdominal pain,
      distension, nausea, and vomiting again. The levels of serum amylase and urine
      amylase were enhanced again. Further imaging examination strongly indicated the
      recurrence of AP. LESSONS: We should raise awareness of the clinicians regarding 
      DIP, thereby enabling its timely diagnosis and accurate treatment, as well as
      promoting the rational and safe use of drugs.
FAU - Cao, Cheng-Liang
AU  - Cao CL
AD  - Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of
      Harbin Medical University, Harbin, Heilongjiang Province, China.
FAU - Duan, Peng-Yu
AU  - Duan PY
FAU - Zhang, Wang-Jun
AU  - Zhang WJ
FAU - Li, Le
AU  - Li L
FAU - Qu, Feng-Zhi
AU  - Qu FZ
FAU - Sun, Bei
AU  - Sun B
FAU - Wang, Gang
AU  - Wang G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cyclobutanes)
RN  - 0 (Organoplatinum Compounds)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - OX5XK1JD8C (lobaplatin)
SB  - AIM
SB  - IM
MH  - Acute Disease
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Cyclobutanes/*adverse effects/therapeutic use
MH  - Diagnosis, Differential
MH  - Drug Therapy, Combination/adverse effects
MH  - Etoposide/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Middle Aged
MH  - Organoplatinum Compounds/*adverse effects/therapeutic use
MH  - Pancreatitis/*chemically induced/*diagnosis
MH  - Small Cell Lung Carcinoma/drug therapy
PMC - PMC5521945
EDAT- 2017/07/21 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/07/21 06:00
AID - 10.1097/MD.0000000000007601 [doi]
AID - 00005792-201707210-00070 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(29):e7601. doi: 10.1097/MD.0000000000007601.